Summary In the year 2000, the ongoing meta-analysis of the Early Breast Cancer Trialists' Collaborative Group will be updated to include additional data from over 4000 patients treated with luteinizing hormone-releasing hormone analogues, principally goserelin. Four major international trials are currently in progress to evaluate the safety and efficacy of goserelin in comparison with the current standard treatments in early breast cancer, which are chemotherapy or tamoxifen. This paper provides an outline of the protocols and main objectives of the Zoladex Early Breast Cancer Research Association (ZEBRA) trial (goserelin versus cyclophosphamide-methotrexate-5-fluorouracil [CMF]), the Cancer Research Campaign (CRC) trial (goserelin versus tamoxifen versus the combination of goserelin and tamoxifen versus no further treatment), the International Breast Cancer Study Group (IBCSG) Vil trial (goserelin versus CMF versus CMF followed by goserelin) and the Eastern Cooperative Oncology Group (ECOG)/South Western Oncology Group (SWOG) trial (cyclophosphamide-doxorubicin-5-fluorouracil [CAF] versus CAF followed by goserelin versus CAF followed by goserelin plus tamoxifen). Preliminary results are expected from the CRC trial in 1998 and from the ZEBRA and ECOG/SWOG trials in 1999. Results from the wide range of comparator regimens, treatment durations and patient subgroups investigated in these trials will greatly increase the clinical database and should help to define the optimum role for goserelin in the treatment of early breast cancer in premenopausal women.
The value of adjuvant ovarian ablation (by irradiation or surgery) in prolonging long-term survival in premenopausal women with early breast cancer has been clearly established. The Early Breast Cancer Trialists' Collaborative Group (EBCTCG) overview of 1996 reported that of 2102 patients under 50 years of age (most of whom would have been premenopausal at diagnosis), those who underwent irreversible ovarian ablation showed a highly significant improvement in both overall and disease-free survival rates compared with controls and that this benefit extended to patients with both node-negative and node-positive disease (Early Breast Cancer Trialists' Collaborative Group, 1996) . This ongoing metaanalysis will be updated in the year 2000 to include additional information from the current trials of ovarian suppression with luteinizing hormone-releasing hormone (LHRH) analogues, most of which involve goserelin. These studies will provide data from over 4000 patients and are the first major trials of adjuvant endocrine therapy since the initiation of the tamoxifen adjuvant trials in 1977. The results of these trials will add considerably to the existing database on the long-term effects of ovarian ablation/suppression in women with early breast cancer, and are keenly awaited.
Goserelin is an established, well-tolerated and convenient therapy for the management of advanced breast cancer in premenopausal and perimenopausal women (Kaufmann et al, 1989 (Kaufmann et al, , 1991 Blamey et al, 1992 Blamey et al, , 1993 Blamey et al, , 1996 . Its potential role as an adjuvant treatment for early disease in such patients, however, remains to be defined. A number of large, randomized, multicentre trials are currently in progress to evaluate the safety and efficacy of goserelin in comparison with the current standard treatments in early breast cancer -chemotherapy or tamoxifen. This paper provides an outline of the protocols and main objectives of these trials.
ZOLADEX EARLY BREAST CANCER RESEARCH ASSOCIATION (ZEBRA) TRIAL
The ZEBRA trial (Blamey et al, 1996; Jonat et al, 1998) Recruitment for this trial commenced in October 1990 and closed in December 1996. The timing of the efficacy analyses is dependent on the number of disease recurrences, but it is hoped that the first data will be available in early 1999.
CANCER RESEARCH CAMPAIGN (CRC) TRIAL
The CRC adjuvant breast cancer trial (Blamey et al, 1996; Wells et al, 1997 ) is a four-arm, multinational, European trial. Approximately 2500 patients under 50 years of age with nodenegative (stage I) or node-positive (stage II) breast cancer have been recruited. After surgery and standard therapy (radiotherapy and/or chemotherapy), if indicated, patients are randomized into four treatment groups to receive: * goserelin, 3.6 mg every 28 days, for 2 years; * tamoxifen, 20 mg daily, for 2 years; * goserelin plus tamoxifen for 2 years; * no further treatment (Figure 2 ).
The objectives of the trial are to determine the effects of ovarian suppression with goserelin, compared with adjuvant tamoxifen or the combination of goserelin plus tamoxifen, on the time to disease recurrence and overall survival rate. A subprotocol is available, if required, to assess the risks and benefits of the different treatment options in patients who received primary radiotherapy. Recruitment commenced in November 1987 and is still continuing (March 1998) . Preliminary results are expected in the near future.
INTERNATIONAL BREAST CANCER STUDY GROUP (IBCSG) VIII TRIAL
The IBCSG VIII trial (Simpson, 1991; Goldhirsch et al, 1994; Blamey et al, 1996) is an intermational study, planning to enrol a minimum of 1200 premenopausal and perimenopausal women with axillary node-negative breast cancer. After surgery, patients are randomized to receive: * goserelin for 2 years; * six cycles of CMF; * six cycles of CMF followed by goserelin for 1.5 years (Figure 3) . This was initially a four-arm trial and included a no-treatment group. However, the fourth treatment arm was discontinued after 2 years of recruitment as it was felt that the benefits of adjuvant therapy were proven in this patient population and it would be unethical to continue with a no-treatment arm.
The objectives of this trial are: * to determine whether the addition of goserelin after six cycles of CMF reduces the relapse rate or prolongs survival compared with either treatment alone;
* to carry out a quality of life analysis to investigate patient well-being during treatment, after treatment but before relapse, and after relapse. (Cheson, 1991; Simpson, 1991; Blamey et al, 1996) . After surgery, patients were randomized to receive:
* six cycles of cyclophosphamide, doxorubicin and 5-fluorouracil (CAF); * six cycles of CAF followed by goserelin, 3.6 mg every 28 days, for 5 years; * six cycles of CAF followed by goserelin plus tamoxifen, 20 mg daily, for 5 years ( Figure 4 ). The objectives of the trial are:
* to compare recurrence rates, disease-free intervals and survival times between the three treatment arms; * to assess the relative toxicity of the three regimens; * to assess the relative effects on hormone levels (luteinizing hormone, oestradiol and follicle-stimulating hormone). 
